PHARMAC undertakes a review on funding for Dexcom G6 CGM technology

With our longstanding support for New Zealanders living with Type 1 diabetes, we are extremely pleased to share that PHARMAC is undertaking a review on CGM funding, following a recommendation by the PTAC Diabetes Subcommittee that the Dexcom G6 CGM system be listed on the Pharmaceutical Schedule with high priority.

This review acknowledges the value of highly clinical, cost-effective CGM technology and its potential to significantly improve health related outcomes for those living with diabetes. Not only are the benefits of CGM reimbursement backed by solid clinical economic evidence, but this investment would align the clinical management of Type 1 diabetes with international best practice and pave the way for a more sustainable healthcare system for New Zealand.

A decision in favour of introducing government-subsidised CGM access for the first time would be welcomed by thousands of New Zealanders living with Type 1 diabetes, as well as diabetes organisations and healthcare professionals.

We encourage the New Zealand diabetes community to voice its support for the introduction of reimbursed CGM access. To help bring about this important change we urge you to support the Diabetes NZ #CGMforAll Campaign. Following their amazing work last year presenting a CGM Petition at the Health Select Committee they will continue to keep this influential government body informed of the life-changing implications that funding CGM will have on people with diabetes. Please follow their campaign on Facebook, Instagram, their website and in the media.